The DOI matches its Crossref record; 95 of the 99 references it cites were found in a registry or an index; 48 of the 101 sources its claims cite were checked for support.
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
Open accessAbstract
Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide and available therapies, including immunotherapies, are ineffective for many patients. HCC is characterized by intratumoral hypoxia, and increased expression of hypoxia-inducible factor 1α (HIF-1α) in diagnostic biopsies is associated with patient mortality...
Overview
CoChat Summary
## TL;DR
This paper identifies 32-134D, a low-molecular-weight HIF inhibitor, as a suppressor of HCC growth that blocks both HIF-1 and HIF-2 activity in human and mouse HCC models. In immunocompetent Hepa1-6 mice, adding 32-134D to anti-PD1 increased complete tumor eradication from 25% to 67%.
## Key findings
- In hypoxic Hep3B cells, 32-134D significantly inhibited HIF-dependent reporter activity with an IC50 of 2.9 μM, and 252 analogs yielded 27 compounds with HIF-transcriptional IC50 values below 3.3 μM.
- In Hep3B xenografts, daily intraperitoneal 32-134D caused partial growth inhibition at 20 mg/kg and maximal inhibition at 40 and 80 mg/kg; treated tumors showed decreased mass and reduced CD31-positive blood vessel area.
- RNA-seq in hypoxic Hep3B cells showed that 3,326 of 3,849 hypoxia-induced genes (86%) were inhibited by 32-134D; overall, 4,689 genes were inhibited, and a 15-gene HIF signature was associated with survival of 364 HCC patients (82 months vs 42 months, P = 0.006).
- In syngeneic Hepa1-6 tumors, 32-134D increased complete responses to anti-PD1 from 25% (3/12) to 67% (8/12), while 32-134D alone eradicated tumors in 4 of 12 mice.
- 32-134D shifted the tumor immune microenvironment toward antitumor immunity: it increased CD8+IFN-γ+ effector T cells, activated CD8+ T cells, and activated NK cells, and decreased TAMs and M-MDSCs; the effector T-cell:TAM ratio increased 3-fold.
- Safety signals were limited in mice: no changes were seen in appearance, behavior, body weight, hemoglobin, hematocrit, serum EPO, or histology of brain, colon, heart, kidney, liver, lungs, or small intestine after 14 days at 40 or 80 mg/kg/day.
## Methods
- The study combined an NCI-60 virtual screen, chemical synthesis of lead analogs, in vitro reporter assays and RT-qPCR, mouse xenograft and syngeneic HCC models, flow cytometry, ELISA, immunohistochemistry, and RNA-seq.
- Human Hep3B and mouse Hepa1-6 HCC cells were used; Hep3B xenografts were grown in nude mice, and Hepa1-6 tumors were grown in C57L mice, with treatment by daily intraperitoneal 32-134D, anti-PD1, or both.
- Main analyses included FLuc/RLuc reporter assays under 1% O2, RT-qPCR/RNA-seq with differential expression thresholds of FDR < 0.05 and fold change > 1.5, tumor immune-cell profiling by flow cytometry, and pharmacokinetics by LC-MS/MS.
## Limitations
- The paper states that further studies are required to determine whether steady-state plasma levels of 32-134D are achieved with daily administration.
- The work is preclinical and limited to cell lines and mouse models; clinical efficacy in humans is not tested in the paper.
- Evident from the text: some mechanistic claims about stromal versus tumor-cell effects are inferential, because differential effects in tumors versus cultured Hepa1-6 cells suggest but do not directly prove the responsible cell types.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
24 Valid · 3 Not valid · 18 Not checked · 97 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Many patients may fail to respond to immune checkpoint inhibitors because of the coexistence of other mechanisms of immune evasion, such as the production of adenosine, which binds to its cognate receptor on T cells to trigger apoptosis (13), or the absence of sufficient T and NK cells in the tumor to serve as targets for anti-PD1 (14).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Disputedcites [13] Huang, 1997, Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion, Blood sourceExperimental — accuracy not yet measured
The citation is attached to the claim that adenosine binds a T-cell receptor to trigger apoptosis, not to the separate claim about insufficient T and NK cells. The Abstract (page unavailable) reports A2a receptor-mediated inhibition of T-cell activation and proliferation at low extracellular adenosine concentrations, but explicitly says direct lymphotoxicity was not observed. It therefore does not support receptor-triggered apoptosis as the mechanism. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [14] sourceExperimental — accuracy not yet measured
The Tailoring cancer immunotherapy section (page unavailable) says tumors with weak lymphocyte infiltration may need treatment that brings tumor-specific T cells into the tumor before anti-PD-1 therapy can be effective. It does not identify a shortage of NK cells as a reason anti-PD-1 lacks targets. Adenosine production is attached to a different citation in the citing sentence, so it is not assessed here. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hypoxia-inducible factors (HIFs) play critical roles in cancer progression by activating the transcription of a large battery of genes encoding proteins that play key roles in angiogenesis, glucose metabolism, invasion/metastasis, stem cell specification, protumoral inflammatory responses, and tumor immune evasion (18, 23–27).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Not checked — no full text of the sourcecites [18] source
- Supportedcites [23] source
The Introduction describes HIFs as important to cancer progression, and ‘HIF activity in breast cancer’ states that HIF induces transcription of target genes. The review also discusses HIF-linked angiogenesis, glucose metabolism, invasion and metastasis, breast cancer stem-cell traits, proinflammatory factors, and an immunosuppressive tumor microenvironment. The claim is a fair synthesis of those passages, though the review focuses on breast cancer; page numbers are not available for most passages in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [24] source
- Not checked — no full text of the sourcecites [25] Semenza, 2021, Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors, Physiology (Bethesda) source
- Partly supportedcites [26] sourceExperimental — accuracy not yet measured
The Introduction describes HIFs as transcription factors and critical drivers of cancer that regulate metabolism, angiogenesis, and invasion/metastasis. The Conclusion and “Hypoxic regulation of tumor immune cell function” also connect HIF signaling to protumor inflammation and suppression of antitumor immunity. Our copy does not support the specific addition of stem cell specification to this list. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [27] Xiang, 2019, Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy, Adv Cancer Res source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intratumoral hypoxia is a major driving force for cancer progression (15–19).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
Section 2 says intratumoral hypoxia in hepatocellular carcinoma induces metabolic changes that promote drug resistance. Section 3.1 links conditions in the tumor microenvironment to faster tumor progression. These passages support a role for hypoxia in progression, but do not establish that it is a major driving force for cancer progression generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [16] source
- Supportedcites [17] source
The Introduction says hypoxia-induced HIF-1α helps tumor cells adapt and thrive and strengthens immunosuppressive signaling. The section “Targeting immunosuppressive hypoxia/HIF-1α axis” also describes the protumor effects of hypoxia, supporting the broad claim that intratumoral hypoxia drives cancer progression. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [18] source
- Not checked — no full text of the sourcecites [19] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mouse models, hypoxic zones within tumors were shown to lack T cells (37, 38).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Partly supportedcites [37] Hatfield, 2015, Immunological mechanisms of the antitumor effects of supplemental oxygenation, Sci Transl Med sourceExperimental — accuracy not yet measured
The Results section reports markedly fewer CD4 and CD8 T cells in hypoxic tumor areas than in neighboring normoxic areas in mouse models. It does not say those areas lack T cells entirely. No page number is provided in our copy. (LLM, conf=0.88)
- Supportedcites [38] source
In the section “Hypoxic zones within prostate tumors lack T cells” and its continuation (page not specified in the excerpt), the authors report that T cells were largely excluded from hypoxic zones in two mouse models of prostate cancer. This supports the citing sentence’s claim about mouse models. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“B7H4 and TIM3 mRNA, which are encoded by the Vtcn1 and Havcr2 genes, respectively, and like PDL1, encode immune checkpoint receptors that are HIF regulated (51, 52) and associated with patient mortality in HCC (53), showed hypoxia-induced expression in vehicle-treated but not in 32-134D–treated cells (P < 0.05; Figure 3B).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Results > Effects of 32-134D on Hepa1-6 mouse HCC cells and tumors.
What the sources say
- Not checked — no full text of the sourcecites [51] source
- Partly supportedcites [52] sourceExperimental — accuracy not yet measured
The Results section, “TIM-3 is elevated in a HIF-1-dependent manner under hypoxia” (page unavailable), reports increased TIM-3 transcripts under hypoxia and HIF-1-dependent regulation in glial cells. It does not report B7H4 expression or the vehicle-versus-32-134D result in Hepa1-6 cells. In the citing sentence, the citations accompany the HIF-regulation background statement; Figure 3B accompanies the cell-treatment result. (LLM, conf=0.88)
- Supportedcites [53] source
Citation 53 supports the sentence’s claim that B7-H4 and TIM-3 are associated with mortality in HCC patients. The Abstract reports that both were independently associated with worse prognosis, and the Discussion links each to worse overall survival. The hypoxia and 32-134D result is attributed to the citing paper’s Figure 3B, not to this source. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
85 more claims · 4 with their cited sources checked
Create a free account to see all 142 claims and every source verdict.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 26
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF‐1α reverses immune dysfunction and overcomes resistance to PD‐L1 blockade.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thus, HIF-1/2α inhibition in mouse models of cancer promotes the efficacy of anti-PD1 therapy and increases infiltration of cytotoxic immune effector cells [84–86].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with this compound reduced HIF-1α and, to a lesser extent, HIF-2α protein levels without altering HIF1A or EPAS1 mRNA expression.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
The cited source says what the claim attributes to it.
In the citing paper
“the small molecule 32-134D was identified as suppressing HIF-α accumulation in hepatocellular carcinoma cell lines.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
The cited source says what the claim attributes to it.
In the citing paper
“Proteasome inhibition abrogated this effect, suggesting enhanced proteasomal turnover of HIF-α subunits, although direct measurements of protein half-life were not performed [334].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Discussion
“In particular, the efficacy of many immunotherapies is dependent on the presence of intratumoral CD8+ T cells, which are significantly increased by treatment with 32-124D.”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Abstract
“Here we report the development of 32-134D, a low-molecular-weight compound that effectively inhibits gene expression mediated by HIF-1 and HIF-2 in HCC cells, and blocks human and mouse HCC tumor growth.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“We previously screened a library of 3,140 drugs and identified acriflavine as a drug that inhibits HIF activity by disrupting subunit dimerization, and blocks HCC tumor growth and vascularization in mouse models (41).”
Cited work 10.1073/pnas.0909353106 · retracted 2023-04-26 · notice 10.1073/pnas.2305537120 · this paper published 2022-05-02
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451 · cited 1×
“We previously screened a library of 3,140 drugs and identified acriflavine as a drug that inhibits HIF activity by disrupting subunit dimerization, and blocks HCC tumor growth and vascularization in mouse models (41).”
BackgroundSelf-citationRetractedModerated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 1×
“quantified with featureCounts (94), and differential gene expres-”
MethodSorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 1×
“5-month improvement in progression-free survival as compared with sorafenib, although more than half of patients receiving the combination therapy suffered grade 3 or 4 adverse events (11).”
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055 · cited 1×
“Nivolumab, an anti-PD1 antibody, was granted FDA approval for HCC based on phase II trial data, but a phase III trial versus sorafenib as first-line therapy did not meet its primary endpoint with respect to overall survival (OS), and a phase III trial of pembrolizumab, another anti-PD1 antibody, also failed versus pla…”
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
“For instance, 32–134D, a low-molecular-weight compound that inhibits HIF-1/2-mediated gene expression in HCC cells, combined with anti-PD-1 increased HCC eradication rates in mice (from 25 to 67%).(401) HIF-1α inhibitors, such as topotecan, bortezomib (PS-341) as well as HIF-2α inhibitors, such as PT2399, PT2385 and P…”
BackgroundHypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 580
“In immunocompetent mice bearing Hepa1-6 mouse HCC tumors, combined treatment with 32-134D and anti–PD-1 antibody resulted in tumor eradication in 67% of the mice compared with 25% of the mice treated with anti–PD-1 alone (177).”
BackgroundInfluentialSelf-citationPD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 246
Self-citationTargeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
“Thus, based on its similarity in gene target induction to acriflavine, 32-134D was recently identified as a nonspecific HIF inhibitor with a chemical structure unrelated to that of acriflavine 59 .”
InfluentialHypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Metadata
- Authors
- Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., Jackson, W., Dordai, D., Rudek, M. A., & Semenza, G. L.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Semenza, Gregg L.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-05-02
- Volume
- 132
- Issue
- 9
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC9057582
- OpenAlex
- W4225257247
- Cited by
- 111
- References
- 99
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 18 · 2023: 29 · 2022: 10
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- American Cancer Society (RP-16-239-06-COUN)
- Armstrong Family Foundation (n/a)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- hepatocellular carcinoma, HIF-1α inhibition, HIF-2α inhibition, anti-PD-1 therapy, combination immunotherapy, tumor hypoxia, tumor immune microenvironment, tumor-associated macrophages, myeloid-derived suppressor cells, CD8+ T cells, natural killer cells, angiogenesis, glycolytic metabolism, immune evasion, antitumor immunity
- MeSH terms
- Animals, Hypoxia, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Neovascularization, Pathologic, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. https://app.cochat.ai/papers/10.1172/jci156774
- The paper
- Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., Jackson, W., Dordai, D., Rudek, M. A., & Semenza, G. L. (2022). HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci156774
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.